Open Access

The clinical significance of preoperative plasma fibrinogen level and platelet count in resectable esophageal squamous cell carcinoma

  • Jianbo Wang1,
  • Hong Liu1,
  • Na Shao2,
  • Bingxu Tan1,
  • Qingxu Song1,
  • Yibin Jia1 and
  • Yufeng Cheng1Email author
Contributed equally
World Journal of Surgical Oncology201513:157

https://doi.org/10.1186/s12957-015-0543-4

Received: 5 August 2014

Accepted: 11 March 2015

Published: 22 April 2015

Abstract

Background

Patients with malignant disease frequently present with activated coagulation pathways, which are potentially associated with tumor progression and prognosis. The aims of the study were to investigate the clinical significance of preoperative plasma fibrinogen level and platelet count in esophageal squamous cell carcinoma (ESCC) treated by curative surgery.

Methods

A total of 119 patients with ESCC treated by curative surgery in Qilu Hospital of Shandong University were included in the study.

Results

The preoperative plasma fibrinogen levels in the patients with ESCC ranged from 2.2 to 6.91 g/L (mean ± SD, 3.85 ± 0.95 g/L). The incidence of hyperfibrinogenemia was 43.7% (52/119, cut-off value 4.0 g/L). Hyperfibrinogenemia was found to be positively correlated with increased tumor length (P = 0.027), increased depth of invasion (P = 0.013), advanced pathological stages (P = 0.011), and disease recurrence (P = 0.026). The platelet counts ranged from 78 × 109/L to 936 × 109/L (mean ± SD, 254.51 ± 89.26 × 109/L). The incidence of thrombocytosis was 20.2% (24/119, cut-off value 300 × 109/L). Thrombocytosis was more frequently seen in male gender (P = 0.029) and non-smokers (P = 0.008). Plasma fibrinogen levels were significantly correlated with platelet counts (r = 0.018, P = 0.048). Hyperfibrinogenemia was significantly associated with poor disease-free (P = 0.009, hazard ratio (HR) = 1.784, 95% confidence interval (CI) = 1.153 to 2.761) and overall (P = 0.003, HR = 1.992, 95% CI = 1.259 to 3.152) survivals in univariate analysis, but not an independent prognostic indicator in multivariate analysis. Thrombocytosis was not significantly associated with disease-free (P = 0.765, HR = 0.918, 95% CI = 0.524 to 1.608) or overall (P = 0.809, HR = 1.072, 95% CI = 0.618 to 1.891) survivals in univariate analysis.

Conclusions

The study suggested that hyperfibrinogenemia is a valuable predictor for disease progression in ESCC. Anticoagulation therapy might be considered to control cancer progression in future studies.

Keywords

Esophageal squamous cell carcinoma Hyperfibrinogenemia Thrombocytosis Prognosis

Background

Esophageal cancer is the eighth most common cancer type and sixth leading cause of cancer death worldwide, which was responsible for 482,300 new cases and 406,800 deaths in 2008 [1]. In some high-risk regions such as North of China, esophageal cancer represents a major health problem, which is the fourth leading cause of cancer death. Squamous cell carcinoma is the major pathological type and accounts for more than 90% of esophageal cancer cases in Chinese patients [2]. Despite the advancement in diagnosis and treatment modalities, esophageal squamous cell carcinoma (ESCC) still shows a dismal prognosis with a 5-year survival rate less than 15% [3,4]. It is important to identify effective biomarkers to recognize unique biological characteristics of ESCC patients, in order to guide more individualized treatment.

It has been demonstrated that the alteration of coagulation pathways was associated with tumor progression and poor prognosis in various malignancies [5,6]. More than half of patients with metastatic disease have some abnormalities in hemostatic parameters [7]. Fibrinogen is a dimeric glycoprotein synthesized by hepatocytes, which plays a key role in clot formation and wound healing. It binds to platelets to support platelet aggregation after being converted to fibrin. Elevated plasma fibrinogen levels reflect a thrombophilic state that arises from the capacity of tumor cells to release coagulant molecules [8]. Fibrinogen is also a pro-inflammatory protein, which usually acts as an acute-phase protein in response to wound healing, infection, and inflammation [9]. Recently, the plasma fibrinogen level was found to correlate with clinicopathological factors and prognosis in gastric cancer, colon cancer, endometrial cancer, and so on [5,10,11]. Platelet is another crucial player of the coagulation system. Platelet could facilitate metastasis through promoting disseminated tumor cell survival in the circulation system, and extravasation and angiogenesis in the microenvironment of target sites [12]. Several studies have demonstrated that an elevated platelet count correlate with poor prognosis in several types of solid cancer, including lung cancer, colorectal cancer, gastric cancer, and so on [13-15]. However, the exact role of plasma fibrinogen level and platelet count in ESCC remains inconclusive.

In the present study, we examined the clinical significance of preoperative plasma fibrinogen level and platelet count in ESCC treated by curative surgery.

Methods

Patients

A total of 119 patients who underwent potential radical surgery for ESCC in Qilu Hospital of Shandong University between 1 January and 30 September 2008 were included in the study. Patients were already excluded because of palliative surgery, neoadjuvant treatment, perioperative mortality, distant metastasis, stage 0 disease, and lost to follow-up. The protocol of the study was approved by the Institutional Ethics Committee of the Qilu Hospital of Shandong University. All the patient demographic and clinical data including age, gender, histological grade, lymph node status, pTNM stage, and adjuvant treatment were abstracted from the clinical records. The stage of disease was determined according to the TNM system of the International Union Against Cancer (6th edition). A thorough histological examination was made using H&E-stained tissue preparations and the histological grade was determined according to the degree of differentiation of the tumor.

Fibrinogen and platelet measurement

As a part of clinical routine, the pretreatment plasma fibrinogen levels and platelet counts were measured from early morning samples and were collected 24 h to 1 week before surgery after overnight fasting. Plasma fibrinogen levels and platelet counts greater than 4.0 g/L and 300 × 109/L were defined as hyperfibrinogenemia and thrombocytosis, respectively, according to the normal reference range in our hospital.

Follow up

Follow-up visit was performed every 3 months for the first 2 years and every 6 months for the next up to death or the end of the study. Data was censored at the last follow-up for patients without recurrence or death. At each visit, a clinical history was taken and a physical examination was performed. Routing diagnostic imaging methods included barium meal fluoroscopy and computer tomography. Disease-free survival (DFS) was defined from the date of the definitive surgery to the date of local or distant recurrence, mortality by any cause, or the last follow-up. Overall survival (OS) was calculated as the time from the date of surgery to that of mortality or censoring.

Statistical analysis

Pretreatment plasma fibrinogen levels and platelet counts were reported as the mean ± SD. Continuous variables in different subgroups were compared using an unpaired t-test and one-way analysis of variance. Categorical variables were compared using chi-square test. Bivariate correlation analysis was performed using Pearson’s correlation coefficient analysis. Kaplan-Meier curves were used to estimate the distribution of DFS and OS, and log-rank test was performed to compare the difference between the survival curves. Variables, which were identified as statistically significant in univariate analysis, were included in the multivariate survival analysis using the Cox proportional hazard model. All statistical analyses were performed using SPSS 13.0 statistical software (SPSS Inc, Chicago, IL, USA). P values <0.05 were considered of statistical significance.

Results

Patient characteristics

Median age was 60 years (range, 42 to 78 years), and 80% of patients were male. Tumor locations were upper thoracic in 15 patients, mid-thoracic in 67 patients, and lower thoracic in 37 patients. The mean length of the tumor was 3.85 cm (range, 0.5 to 8.5). The histopathological differentiations were poor in 35 cases, moderate in 51 cases, and well in 33 cases. 75 patients (63%) had T3/T4 tumors. Forty-four patients (27%) have positive lymph nodes. The pathological stages were stage I in 21 patients, stage II in 58 patients and stage III in 40 patients. 71 patients (59.7%) received surgery alone, 11 (9.2%) received postoperative chemotherapy, 25 (21%) received postoperative radiotherapy, and 12 (10.1%) received postoperative chemoradiation. Eighty-one patients (68.1%) had recurrence, and 74 (62.2%) died during the follow-up. The estimated 1-, 3-, and 5-year DFS and OS rates were 75%, 49%, and 37% and 87%, 55%, and 41%, respectively. Median DFS was 33.8 months (range, 1.5 to 71.5 months). Median OS was 45.8 months (range, 2.6 to 71.5 months).

Correlation between plasma fibrinogen, platelet count, and clinicopathological parameters

The plasma fibrinogen levels in preoperative esophageal cancer patients ranged from 2.2 to 6.91 g/L (mean ± SD 3.85 ± 0.95 g/L). The incidence of hyperfibrinogenemia was 43.7% (52/119, cut-off value 4.0 g/L). Hyperfibrinogenemia was found to be positively correlated with a larger tumor size (P = 0.027), increased depth of invasion (P = 0.013), advanced pathological stages (P = 0.011), and disease recurrence (P = 0.026). No significant correlation was identified between fibrinogen levels and tumor location or lymph node metastasis (Table 1).
Table 1

Relationship of preoperative plasma fibrinogen level with clinicopathological parameter

Variable

N

Fibrinogen level

P value

Fibrinogen level

P value

  

Mean ± SD

 

Normal

Hyperfibrinogenemia

 

(g/L)

(1.5 to 4 g/L)

(≥4 g/L)

Gender

      

  Male

95

3.94 ± 0.98

0.034

51

44

0.252

  Female

24

3.48 ± 0.73

 

16

8

 

Age

      

  <60

59

3.7 ± 0.94

0.101

38

21

0.077

  ≥60

60

3.99 ± 0.95

 

29

31

 

Smoking history

      

  Yes

71

3.91 ± 0.95

0.371

29

19

0.457

  No

48

3.75 ± 0.96

 

38

33

 

Location

      

  Upper

15

3.56 ± 0.74

0.144

9

6

0.528

  Middle

67

3.78 ± 0.99

 

40

27

 

  Lower

37

4.08 ± 0.93

 

18

19

 

Tumor length

      

  <3.85 cm

64

3.56 ± 0.88

<0.001

42

22

0.027

  ≥3.85 cm

55

4.18 ± 0.93

 

25

30

 

Differentiation

      

  Well

33

3.94 ± 0.81

0.782

17

16

0.676

  Moderate

51

3.81 ± 1.09

 

31

20

 

  Poor

35

3.8 ± 0.87

 

19

16

 

Tumor stage

      

  T1

18

3.25 ± 0.68

0.001

15

3

0.013

  T2

26

3.67 ± 0.91

 

17

9

 

  T3

67

3.97 ± 0.92

 

33

34

 

  T4

8

4.69 ± 1.11

 

2

6

 

Lymph node status

      

  Negative

75

3.77 ± 0.94

0.267

46

29

0.149

  Positive

44

3.97 ± 0.97

 

21

23

 

Pathological stages

      

  I

21

3.48 ± 0.81

0.034

15

6

0.011

  II

58

3.79 ± 0.98

 

37

21

 

  III

40

4.12 ± 0.91

 

15

25

 

Adjuvant treatment

      

  None

71

3.87 ± 0.95

0.962

37

34

0.307

  Radiotherapy

25

3.83 ± 0.97

 

13

12

 

  Chemotherapy

11

3.9 ± 0.82

 

8

3

 

  CRT

12

3.72 ± 1.11

 

9

3

 

Recurrence

      

  Yes

81

3.94 ± 0.97

0.116

40

41

0.026

  No

38

3.65 ± 0.89

 

27

11

 

SD, standard deviation; CRT, chemoradiotherapy. P < 0.05 is of significance.

The platelet counts ranged from 78 × 109/L to 936 × 109/L (mean ± SD 254.51 ± 89.26 × 109/L). The incidence of thrombocytosis was 20.2% (24/119, cut-off value 300 × 109/L). Thrombocytosis was more frequently seen in male gender (P = 0.029) and non-smokers (P = 0.008). There was no significant correlation between the platelet count and the larger tumor size, increased depth of invasion, advanced pathological stages, or disease recurrence (Table 2). A significant correlation between plasma fibrinogen levels and platelet counts was observed (r = 0.018, P = 0.048).
Table 2

Relationship of preoperative platelet count with clinicopathological parameters

Variable

N

Platelet count

P value

Platelet count

P value

  

Mean ± SD

 

Normal

Thrombocytosis

 
  

(×109/L)

 

<300 × 109/L

≥300 × 109/L

 

Gender

      

  Male

95

260.79 ± 96.13

0.127

72

23

0.029

  Female

24

229.67 ± 47.93

 

23

1

 

Age

      

  <60

59

254.86 ± 68.78

0.966

46

13

0.615

  ≥60

60

254.17 ± 106.22

 

49

11

 

Smoking history

      

  Yes

71

267.39 ± 105.4

0.055

44

4

0.008

  No

48

235.46 ± 53.23

 

51

20

 

Location

      

  Upper

15

260.93 ± 82.51

0.696

12

3

0.964

  Middle

67

248.36 ± 59.93

 

54

13

 

  Lower

37

263.05 ± 129.3

 

29

8

 

Tumor length

      

  <3.85 cm

64

250.18 ± 103.94

0.571

54

10

0.183

  ≥3.85 cm

55

259.54 ± 68.96

 

41

14

 

Differentiation

      

  Well

33

263.39 ± 136.03

0.793

26

7

0.568

  Moderate

51

250.04 ± 69.68

 

39

12

 

  Poor

35

252.66 ± 54.62

 

30

5

 

Tumor stage

      

  T1

18

207.56 ± 51.84

0.034

17

1

0.251

  T2

26

247.58 ± 53.27

 

21

5

 

  T3

67

263.66 ± 105.27

 

52

15

 

  T4

8

306.13 ± 58.73

 

5

3

 

Lymph node status

      

  Negative

75

250.89 ± 99.45

0.566

62

13

0.314

  Positive

44

260.68 ± 69.14

 

33

11

 

Pathological stages

      

  I

21

258.19 ± 168.65

0.233

17

4

0.636

  II

58

246.48 ± 54.6

 

48

10

 

  III

40

264.23 ± 70.43

 

30

10

 

Adjuvant treatment

      

  None

71

259.69 ± 105.06

0.823

56

15

0.788

  Radiotherapy

25

253.48 ± 65.68

 

20

5

 

  Chemotherapy

11

235.55 ± 43.03

 

10

1

 

  CRT

12

243.42 ± 58.82

 

9

3

 

Recurrence

      

  Yes

 

251.44 ± 58.06

0.675

66

15

0.513

  No

 

261.05 ± 134.37

 

29

9

 

SD, standard deviation; CRT, chemoradiotherapy. P < 0.05 is of significance.

Survival analysis

We assessed the prognostic values of the preoperative plasma fibrinogen level and platelet count in the ESCC patients included in our study, as shown in Table 3. Patients with hyperfibrinogenemia had lower 5-year disease-free survival (27% vs. 45%) and overall survival rates (29% vs. 51%) than those with normal plasma fibrinogen concentration. In univariate analysis, hyperfibrinogenemia was associated with poor disease-free (P = 0.009, hazard ratio (HR) = 1.784, 95% confidence interval (CI) = 1.153 to 2.761) and overall (P = 0.003, HR = 1.992, 95% CI = 1.259 to 3.152) survivals (Figure 1). Thrombocytosis was not correlated with disease survivals. Clinicopathological factors, which significantly associated with poor disease-free and overall survivals, were advanced T stages, lymph node metastasis, and advanced pTNM stages. In multivariate analysis, only pTNM stages were an independent predictor for disease-free survival (P < 0.001, HR = 2.985, 95% CI = 1.898 to 4.695), and both depth of invasion (P = 0.025, HR = 1.895, 95% CI = 1.084 to 3.313) and pTNM stages (P < 0.001, HR = 2.501, 95% CI = 1.52 to 4.114) were independent prognostic factors for overall survival.
Table 3

Univariate analysis of survival of esophageal squamous cell carcinoma treated by curative surgery

Variable

Disease-free survival

P value

Overall survival

P value

HR (95% CI)

HR (95% CI)

Gender (Female)

0.939(0.535 to 1.647)

0.826

0.937(0.523 to 1.677)

0.826

Age (≥60)

0.982(0.634 to 1.519)

0.933

1.09(0.69 to 1.721)

0.712

Smoking history

1.093(0.697 to 1.717)

0.698

1.139(0.712 to 1.825)

0.587

Location

    

  Upper

Ref.

0.432

Ref.

0.652

  Middle

0.656(0.346 to 1.246)

0198

0.721(0.36 to 1.442)

0.355

  Lower

0.694(0.349 to 1.378)

0.296

0.771(0.368 to 1.614)

0.49

Tumor length (≥3.85 cm)

1.178(0.761 to 1.824)

0.462

1.335(0.846 to 2.106)

0.215

Differentiation

    

  Well

Ref.

0.2

Ref.

0.141

  Moderate

1.595(0.915 to 2.781)

0.1

1.69(0.931 to 3.067)

0.084

  Poor

1.616(0.889 to 2.939)

0.116

1.819(0.965 to 3.427)

0.064

Tumor stage

    

  T1

Ref.

0.011

Ref.

0.001

  T2

1.388(0.612 to 3.149)

0.432

1.591(0.605 to 4.188)

0.347

  T3

2.295(1.117 to 4.713)

0.024

3.19(1.36 to 7.481)

0.008

  T4

4.112(1.568 to 10.786)

0.004

5.968(2.058 to 17.301)

0.001

Lymph node metastasis

2.406(1.544 to 3.749)

<0.001

2.414(1.522 to 3.829)

<0.001

Pathological stages

    

  I

Ref.

<0.001

Ref.

<0.001

  II

1.97(0.944 to 4.113)

0.071

2.561(1.069 to 6.133)

0.035

  III

4.96(2.35 to 10.471)

<0.001

6.412(2.669 to 15.404)

<0.001

Adjuvant treatment

    

  None

Ref.

0.133

Ref.

0.073

  Radiotherapy

1.672(0.984 to 2.839)

0.057

1.814(1.058 to 3.111)

0.03

  Chemotherapy

0.732(0.312 to 1.714)

0.472

0.652(0.258 to 1.65)

0.367

  CRT

1.549(0.756 to 3.174)

0.232

1.521(0.712 to 3.249)

0.279

Fibrinogen level (≥4 g/L)

1.784(1.153 to 2.761)

0.009

1.992(1.259 to 3.152)

0.003

Platelet count (≥300 × 109 /L)

0.918(0.524 to 1.608)

0.765

1.072(0.618 to 1.891)

0.809

HR, hazard ratio; CI, confidence interval; CRT, chemoradiotherapy. P < 0.05 is of significance.

Figure 1

Kaplan-Meier analysis of preoperative plasma fibrinogen level in 119 patients with esophageal squamous cell carcinoma. Hyperfibrinogenemia were significantly associated with decreased disease-free survival (A) and overall survival (B).

Discussion

Recently, much attention has been paid to the relationship between hyperfibrinogenemia/thrombocytosis and malignant diseases. Elevated plasma fibrinogen levels and platelet counts have been found in some malignancies, such as gastric cancer, colorectal cancer, lung cancer, and so on [11,16-18]. In the present study, we analyzed the clinical significance of preoperative plasma fibrinogen level and platelet count in 119 patients with ESCC received curative surgery. We found that the incidence of hyperfibrinogenemia and thrombocytosis were 43.7% (52/119, cut-off value 4.0 g/L) and 20.2% (24/119, cut-off value 300 × 109/L), respectively, in the resectable ESCC patients. Hyperfibrinogenemia was found to be positively correlated with the increased tumor length, increased depth of invasion, and advanced pathological stages. Hyperfibrinogenemia was associated with poor disease-free and overall survivals in univariate analysis, but not an independent predictor for prognosis in multivariate analysis. Thrombocytosis was not associated with clinical outcome and clinicopathological parameters such as depth of invasion, lymph node metastasis, or pathological stages. We also observe a significant correlation plasma fibrinogen levels and platelet counts (r = 0.018, P = 0.048).

To our best knowledge, only two studies analyzed the clinical significance of plasma fibrinogen in ESCC. Takeuchi et al. [19] showed that pretreatment plasma fibrinogen correlates with tumor progression and metastasis in patients with ESCC. However, they did not show any association of pretreatment plasma fibrinogen with survivals in patients treated by surgery. Matsuda and colleagues [20] found that plasma fibrinogen level as a predictive marker for postoperative recurrence of ESCC in patients receiving neoadjuvant treatment. In the study, we firstly analyzed the clinical significance of pretreatment plasma fibrinogen in 119 ESCC treated by curative surgery without neoadjuvant treatment. Our study showed that hyperfibrinogenemia was significantly associated with advanced disease.

For thrombocytosis, the role of its prognostic significance is also inconclusive. Feng et al. [21] analyzed the clinical significance of preoperative thrombocytosis in a group of patients with ESCC and found that preoperative platelet count is a predictive factor for long-term survival in ESCC, especially in node-positive patients. Shimada et al. [22] found that a high platelet count is associated with tumor progression and poor survival in patients with esophageal cancer. However, the present study did not show that thrombocytosis was associated with clinical outcome and any pathological parameters in ESCC treat by curative surgery. The reason for the inconsistent results may be that our study included patients with relative early stage compared with previous studies.

The exact mechanism linking coagulation pathways and cancer progression remains unclear. Fibrinogen is a dimeric molecule with multiple integrin and non-integrin binding motifs, and cancer cells often express high levels of integrins or intercellular adhesion molecule 1. Fibrinogen deposition around tumor cells enhances the interaction between these cells and platelets, which effectively form microemboli in target organs [23]. Fibrinogen may also bind to growth factors, such as fibroblast growth factors and vascular endothelial cell growth factors, and thereby regulate endothelial cell proliferation and angiogenesis [24]. Fibrinogen layers help tumor cells block natural killer cytotoxicity with thrombin, which can protect tumor cells from the innate immune system [25].

Platelets, which were produced by mature bone marrow megakaryocytes, play an important role in arresting hemorrhage after tissue trauma or vascular injury. Platelets take an active part in the initiation and development of the inflammatory process by adhering to the cells of the vascular walls and by releasing of chemokines, cytokines, proteases, and procoagulants [26]. Platelets release various cytokines, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), during blood clotting. The VEGF and PDGF family of proteins have a significant role in regulating tumor cell growth and angiogenesis [27]. Moreover, platelets expressing immunoregulatory protein such as glucocorticoid-induced TNF-related protein may protect the cancer cells from the host’s immune system [28].

The potential limitations of the present study include the use of a retrospective design. In order to select patients with a more uniform background, we only included esophageal cancer patients treated by potential curative surgery and excluded those received neoadjuvant treatment, which may also limit the general application of the results. Furthermore, larger prospective studies will be needed to confirm these preliminary results.

Conclusions

Our study demonstrated that hyperfibrinogenemia is a valuable predictor for disease progression in ESCC. Anticoagulation therapy might be considered to control cancer progression in future studies. Additionally, the introduction of the convenient prognostic factors such as plasma fibrinogen can assist clinicians with better individualization of their therapeutic approach based on the risk stratification.

Consent

Written informed consent was obtained from the patients for the publication of this report and any accompanying images.

Notes

Declarations

Acknowledgements

The work was supported by Science and Technology plan project of Shandong Province 2012GSF11852 and Natural Science Fund of Shandong Province 2010ZRE27212.

Authors’ Affiliations

(1)
Department of Radiation, Qilu Hospital of Shandong University
(2)
Departments of Oncology, Shandong Provincial Hospital Affiliated to Shandong University

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.View ArticlePubMedGoogle Scholar
  2. Mao YS, He J, Cheng GY. Current status of surgical management of esophageal cancer in China and the future strategy. Zhonghua Zhong Liu Za Zhi. 2010;32:401–4.PubMedGoogle Scholar
  3. Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol. 2007;25:4110–7.View ArticlePubMedGoogle Scholar
  4. Cheng TH, Hsu PK, Li AF, Hung IC, Huang MH, Hsu HS. Correlation of p53, MDM2 and p14(ARF) protein expression in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2009;135:1577–82.View ArticlePubMedGoogle Scholar
  5. Son HJ, Park JW, Chang HJ, Kim DY, Kim BC, Kim SY, et al. Preoperative plasma hyperfibrinogenemia is predictive of poor prognosis in patients with nonmetastatic colon cancer. Ann Surg Oncol. 2013;20:2908–13.View ArticlePubMedGoogle Scholar
  6. Sheng L, Luo M, Sun X, Lin N, Mao W, Su D. Serum fibrinogen is an independent prognostic factor in operable nonsmall cell lung cancer. Int J Cancer. 2013;133:2720–5.View ArticlePubMedGoogle Scholar
  7. Kilic M, Yoldas O, Keskek M, Ertan T, Tez M, Gocmen E, et al. Prognostic value of plasma D-dimer levels in patients with colorectal cancer. Colorectal Dis. 2008;10:238–41.View ArticlePubMedGoogle Scholar
  8. Gouin-Thibault I, Achkar A, Samama MM. The thrombophilic state in cancer patients. Acta Haematol. 2001;106:33–42.View ArticlePubMedGoogle Scholar
  9. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.View ArticlePubMed CentralPubMedGoogle Scholar
  10. Ghezzi F, Cromi A, Siesto G, Giudici S, Serati M, Formenti G, et al. Prognostic significance of preoperative plasma fibrinogen in endometrial cancer. Gynecol Oncol. 2010;119:309–13.View ArticlePubMedGoogle Scholar
  11. Yamashita H, Kitayama J, Nagawa H. Hyperfibrinogenemia is a useful predictor for lymphatic metastasis in human gastric cancer. Jpn J Clin Oncol. 2005;35:595–600.View ArticlePubMedGoogle Scholar
  12. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11:123–34.View ArticlePubMedGoogle Scholar
  13. Gonzalez Barcala FJ, Garcia Prim JM, Moldes Rodriguez M, Alvarez Fernandez J, Rey Rey MJ, Pose Reino A, et al. Platelet count: association with prognosis in lung cancer. Med Oncol. 2010;27:357–62.View ArticlePubMedGoogle Scholar
  14. Wan S, Lai Y, Myers RE, Li B, Hyslop T, London J, et al. Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. J Gastrointest Cancer. 2013;44:293–304.View ArticlePubMed CentralPubMedGoogle Scholar
  15. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002;9:287–91.View ArticlePubMedGoogle Scholar
  16. Tang L, Liu K, Wang J, Wang C, Zhao P, Liu J. High preoperative plasma fibrinogen levels are associated with distant metastases and impaired prognosis after curative resection in patients with colorectal cancer. J Surg Oncol. 2010;102:428–32.View ArticlePubMedGoogle Scholar
  17. Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J. 1996;9:1826–30.View ArticlePubMedGoogle Scholar
  18. Wang H, Gao J, Bai M, Liu R, Li H, Deng T, et al. The pretreatment platelet and plasma fibrinogen level correlate with tumor progression and metastasis in patients with pancreatic cancer. Platelets. 2014;25:382–7.View ArticlePubMedGoogle Scholar
  19. Takeuchi H, Ikeuchi S, Kitagawa Y, Shimada A, Oishi T, Isobe Y, et al. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol. 2007;22:2222–7.View ArticlePubMedGoogle Scholar
  20. Matsuda S, Takeuchi H, Fukuda K, Nakamura R, Takahashi T, Wada N, et al. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment. Dis Esophagus. 2014;27:654–61.View ArticlePubMedGoogle Scholar
  21. Feng JF, Huang Y, Lu WS, Chen QX. Preoperative platelet count in esophageal squamous cell carcinoma: is it a prognostic factor? Langenbecks Arch Surg. 2013;398:1115–22.View ArticlePubMedGoogle Scholar
  22. Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H, et al. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg. 2004;198:737–41.View ArticlePubMedGoogle Scholar
  23. Yano HJ, Hatano K, Tsuno N, Osada T, Watanabe T, Tsuruo T, et al. Clustered cancer cells show a distinct adhesion behavior from single cell form under physiological shear conditions. J Exp Clin Cancer Res. 2001;20:407–12.Google Scholar
  24. Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood. 2000;96:3772–8.PubMedGoogle Scholar
  25. Zheng S, Shen J, Jiao Y, Liu Y, Zhang C, Wei M, et al. Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity. Cancer Sci. 2009;100:859–65.View ArticlePubMedGoogle Scholar
  26. Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev. 2009;23:177–89.View ArticlePubMed CentralPubMedGoogle Scholar
  27. Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther. 2008;8:1247–55.View ArticlePubMedGoogle Scholar
  28. Placke T, Kopp HG, Salih HR. Modulation of natural killer cell anti-tumor reactivity by platelets. J Innate Immun. 2011;3:374–82.View ArticlePubMedGoogle Scholar

Copyright

© Wang et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement